TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07064759: A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults With Macular Neovascularization Secondary to Age-Related Macular Degeneration

Sponsor: 4D Molecular Therapeutics · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 480 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$754,304

Rescue Site Savings

+$518,584

Unlock Full NCT07064759 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07064759 Rescue Dossier →